Johnson & Johnson Pte Ltd today announced new data from a post-hoc analysis of the Phase 3 COU-AA-302 trial. The new data showed that abiraterone acetate plus prednisone demonstrated an unprecedented 11.8 months median life extension (53.6 months vs 41.8 months), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer.
Presented on the sidelines of the 14th Urological Association of Asia Congress 2016 (20 – 24 July), the post-hoc analysis showed an overall survival (OS) benefit, as well as improvement in three areas compared to placebo plus prednisone: disease progression, cancer-related pain and treatment duration1:
- Time to chemotherapy use was increased by 12.7 months in Group 1 (less symptomatic stage of disease) and 8.8 months in Group 2 (more advanced stage of disease)
- There was an improvement in median time to opiate use for cancer-related pain (Group 1: not reached vs 41.0 months; Group 2: 30.5 months vs 19.3 months)
- Median time on treatment almost doubled in both groups (Group 1: 20.4 months vs 11.2 months; Group 2: 12.3 months vs 7.2 months)
Professor Kurt Miller, Department of Urology, Charité Berlin, Berlin, Germany said: “Post-hoc analyses such as this play an important role in determining a patient’s treatment plan. This is because data such as this may help healthcare practitioners identify patients who could benefit most from therapies as well as the efficacy of the therapies at different stages of the disease.”
According to the Singapore Cancer Registry, prostate cancer is the third most common cancer amongst Singaporean males. Out of all the cases diagnosed, advanced (stage IV) prostate cancer comprises nearly 30 per cent. Metastatic prostate cancer is the stage where prostate cancer cells have spread outside the prostate to other parts of the body. Metastatic castration-resistant prostate cancer is when these advanced cancers no longer respond to the usual treatment method, hormone therapy, which aims to lower androgen levels by either medical or surgical castration.
Associate Professor Edmund Chiong, President of the Singapore Urological Association (SUA) and Senior Consultant Urologist at the National University Hospital (NUH) said: “As healthcare practitioners, we often receive questions on survival duration from patients with cancer. Whilst aiming to prolong survival time for patients with advanced cancer is important, management strategies that involve maintaining quality of life and delaying symptoms progression of the cancer, also form integral parts of holistic cancer care.”